Scholar Rock Holding Corporation (SRRK)
Health Care ยท Biological Products, (No Diagnostic Substances)
Scholar Rock Holding Corporation (SRRK) is listed on Nasdaq, where its shares have traded since May 24, 2018. SentiSense covers Scholar Rock Holding Corporation in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). David Hallal is its chief executive officer. The company reports 289 employees, and its corporate website is www.scholarrock.com.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Latest reported results
Scholar Rock Holding Corp. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 295 institutions reported holding SRRK, with 138.5 million shares worth $7.6 billion in aggregate. The largest reported holders were FMR, Siren and BlackRock. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on SRRK
- SRRK sentiment: whether news and social coverage of Scholar Rock Holding Corporation leans bullish or bearish, and the stories driving it.
- SRRK ownership: all 295 reporting institutions, plus insider and congressional trades.
- SRRK financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Scholar Rock Holding Corporation do?
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases.
What sector is SRRK in?
SentiSense classifies Scholar Rock Holding Corporation in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does SRRK stock trade?
Scholar Rock Holding Corporation (SRRK) is listed on Nasdaq, where its shares have traded since May 24, 2018.
Who is the CEO of Scholar Rock Holding Corporation?
David Hallal is the chief executive officer of Scholar Rock Holding Corporation.